Rapiblyk (landiolol) - AOP Orphan Pharma
Study on the safety and effectiveness of Landilol in preventing new-onset atrial fibrillation after off-pump coronary artery bypass grafting (ChiCTR) - Oct 16, 2026 - P=N/A | N=264 | Not yet recruiting | Sponsor: Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Capital Medical University 
New trial • Atrial Fibrillation • Cardiovascular
https://www.chictr.org.cn/showproj.html?proj=346468
 
Oct 16, 2026
 
Prev Next